MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-15-2024
VBI Vaccines Market Cap 2011-2026 | VBIV
As of April 07, 2026 VBI Vaccines has a market cap of $ 1.09 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap VBI Vaccines
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.65 M | 3.1 M | 597 M | 765 M | 166 M | 108 M | 176 M | 114 M | 68.3 M | 42.8 M | 60.4 M | 27 M | 160 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 765 M | 3.1 M | 177 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
116 M | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Entera Bio Ltd.
ENTX
|
30.6 M | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Equillium
EQ
|
118 M | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Evogene Ltd.
EVGN
|
66.3 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
187 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
335 M | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 6.2 | -3.43 % | $ 177 M | USA |
|
Foghorn Therapeutics
FHTX
|
356 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
4.43 B | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
62.9 B | $ 88.37 | -3.19 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
539 K | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
183 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
1.25 M | $ 0.54 | 4.26 % | $ 503 K | Israel |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genmab A/S
GMAB
|
25 B | $ 27.13 | -2.25 % | $ 17 B |  Danmark |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |